Skip to main content

The DECLARE-TIMI 58 trial

Update 06-13-2019 | Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Presenters: Itamar Raz, MD; Stephen D. Wiviott, MD, FACC; John P. Wilding, DM, FRCP; Lawrence A. Leiter, MD, FRCPC, FACP, FACE, FAHA, FACC. 

Sunday 9 June: 14:15–16:15

This trial testing the cardiovascular safety of dapagliflozin showed significant protective effects on heart failure and cardiovascular death, and on the secondary endpoint of composite renal outcomes. But in line with other medications in the sodium-glucose cotransporter 2 (SGLT2) inhibitors class, it had little or no effect on atherosclerotic outcomes.

More on this trial